ANNX Share Price Performance
US$2.35
-3.04 (-56.40%)
Price US$2.35
Share PriceUS$2.35
ANNX Community Narratives
There are no narratives available yet.
Recent ANNX News & Updates
No updates
Annexon, Inc. Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.53
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 0%
Annexon, Inc. Competitors
About ANNX
- Founded
- 2011
- Employees
- 106
- CEO
- WebsiteView website
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company’s lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
U.S. Market Performance
- 7 Days: -0.2%
- 3 Months: 12.2%
- 1 Year: 22.4%
- Year to Date: 7.7%
The Communication Services sector gained 3.4% while the market remained flat over the last week. As for the longer term, the market has risen 22% in the past 12 months. Looking forward, earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading